Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) will showcase its transformation and growth plan at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 2:20 p.m. EDT. Paul J. Diaz, president and CEO, will lead the discussion. The presentation will be accessible through a live audio webcast available on Myriad's website, aimed at advancing genetic testing and precision medicine. Recognized by Fast Company as one of the World’s Most Innovative Companies for 2022, Myriad is dedicated to improving patient care and reducing healthcare costs through its genetic tests.
- None.
- None.
SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT.
The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
| Media Contact: | Investor Contact: |
| Megan Manzari | Nathan Smith |
| (385) 318-3718 | (801) 505-5067 |
| Megan.Manzari@myriad.com | Nathan.Smith@myriad.com |
FAQ
What is the date and time for Myriad Genetics' presentation at the Bank of America Securities 2022 Healthcare Conference?
Who will be speaking at the Bank of America Securities 2022 Healthcare Conference for Myriad Genetics?
How can I access the Myriad Genetics presentation at the Bank of America Securities Conference?
What recognition did Myriad Genetics receive in 2022?
